Filoviruses Require Endosomal Cysteine Proteases for Entry but Exhibit Distinct Protease Preferences

Journal of Virology

Volumn 86, Issue 6, 2012, Pages 3284-3292

  Misasi, John ^a,b   Chandran, Kartik ^a,f   Yang, Jin Yi ^a   Considine, Bryden ^a,b   Filone, Claire Marie ^a,c   Côté, Marceline ^a   Sullivan, Nancy ^d   Fabozzi, Giulia ^d   Hensley, Lisa ^c   Cunninghama, James ^a,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CATHEPSIN B INHIBITOR; CATHEPSIN L; CYSTEINE PROTEINASE; GLYCOPROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EBOLA VIRUS; EMBRYO; ENZYME POLYMORPHISM; ENZYME SPECIFICITY; FILOVIRUS; FILOVIRUS INFECTION; GENETIC VARIABILITY; MOUSE; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; VIRUS ENTRY; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS STRAIN;

ANIMALS; CELL LINE; CYSTEINE PROTEASES; EBOLAVIRUS; ENDOSOMES; HEMORRHAGIC FEVER, EBOLA; HUMANS; MARBURG VIRUS DISEASE; MARBURGVIRUS; SPECIES SPECIFICITY; VIRUS INTERNALIZATION;

EBOLA VIRUS; FILOVIRIDAE; LAKE VICTORIA MARBURGVIRUS;

EID: 84863230082     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06346-11     Document Type: Article

References (46)

1. Alvarez CP, et al. 2002. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 76:6841-6844.
2. Arthos J, et al. 1989. Identification of the residues in human CD4 critical for binding HIV. Cell 57:469-481.
3. Brecher M, et al. 2012. Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J. Virol. 86:364-372.
4. Brindley M, et al. 2007. Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. J. Virol. 81:7702-7709.
5. Carette JE, et al. 2011. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477:340-343.
6. Centers for Disease Control and Prevention. 2001. Outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001. MMWR Morb. Mortal. Wkly. Rep. 50:73-77.
7. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. 2005. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643-1645.
8. Colebunders R, Borchert M. 2000. Ebola haemorrhagic fever-a review. J. Infect. 40:16-20.
9. Colebunders R, et al. 2007. Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness, and treatment. J. Infect. Dis. 196(Suppl. 2):S148-S153.
10. Côté M, et al. 2011. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477:344-348. (Letter.)
11. Dias J, et al. 2011. A shared structural solution for neutralizing ebolaviruses. Nat. Struct. Mol. Biol. 18:1424-1427.
12. Dube D, et al. 2009. The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J. Virol. 83: 2883-2891.
13. Dube D, et al. 2010. Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry. Proc. Natl. Acad. Sci. U. S. A. 107:16637-16642.
14. Fabozzi G, Nabel C, Dolan M, Sullivan N. 2011. Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J. Virol. 85:2512-2523.
15. Fujishima A, et al. 1997. The crystal structure of human cathepsin L complexed with E-64. FEBS Lett. 407:47-50.
16. Geisbert TW, Jahrling PB. 2004. Exotic emerging viral diseases: progress and challenges. Nat. Med. 10:S110-S121.
17. Guncar G, Pungercic G, Klemencic I, Turk V, Turk D. 1999. Crystal structure ofMHCclass II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S. EMBO J. 18:793-803.
18. Harrison SC. 2008. Viral membrane fusion. Nat. Struct. Mol. Biol. 15: 690-698.
19. Hood CL, et al. 2010. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J. Virol. 84:2972-2982.
20. Hunt CL, Kolokoltsov AA, Davey RA, Maury W. 2011. The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus. J. Virol. 85:334-347.
21. Kaletsky R, Simmons G, Bates P. 2007. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J. Virol. 81:13378-13384.
22. Kondratowicz AS, et al. 2011. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc. Natl. Acad. Sci. U. S. A. 108:8426-8431.
23. Kuhn JH, et al. 2010. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch. Virol. 155:2083-2103.
24. Kuhn JH, et al. 2006. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J. Biol. Chem. 281:15951-15958.
25. Lee JE, et al. 2008. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454:177-182.
26. Li F, Li W, Farzan M, Harrison SC. 2005. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309: 1864-1868.
27. Lin G, et al. 2003. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J. Virol. 77:1337-1346.
28. Manicassamy B, Wang J, Jiang H, Rong L. 2005. Comprehensive Analysis of ebola virus GP1 in viral entry. J. Virol. 79:4793-4805.
29. Marzi A, et al. 2006. The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR. J. Virol. 80:6305-6317.
30. Mulherkar N, Raaben M, de la Torre JC, Whelan SP, Chandran K. 2011. The Ebola virus glycoprotein mediates entry via a non-classical dynamindependent macropinocytic pathway. Virology 419:72-83.
31. Nanbo A, et al. 2010. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog. 6(9):e1001121.
32. Otto H-H, Schirmeister T. 1997. Cysteine proteases and their inhibitors. Chem. Rev. 97:133-172.
33. Ribeiro RM, Hazenberg MD, Perelson AS, Davenport MP. 2006. Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J. Virol. 80:802-809.
34. Saeed MF, Kolokoltsov A, Albrecht T, Davey R. 2010. Cellular entry of Ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog. 6:e1001110.
35. Schornberg K, et al. 2006. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 80:4174-4178.
36. Schornberg K, et al. 2009. α5β1-integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc. Natl. Acad. Sci. U. S. A. 106:8003-8008.
37. Simmons G, et al. 2003. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 305:115-123.
38. Stevens J, et al. 2006. Structure and receptor specificity of hemagglutinin from an H5N1 influenza virus. Science 312:404-410.
39. Towner JS, et al. 2008. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 4:e1000212.
40. Turk B, Turk D, Turk V. 2000. Lysosomal cysteine proteases: more than scavengers. Biochim. Biophys. Acta 1477:98-111.
41. Turk D, Podobnik M, Kuhelj R, Dolinar M, Turk V. 1996. Crystal structures of human procathepsin B at 3.2 and 3.3 Angstroms resolution reveal an interaction motif between a papain-like cysteine protease and its propeptide. FEBS Lett. 384:211-214.
42. Turk D, Guncar G. 2003. Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr. D Biol. Crystallogr. 59(Pt. 2): 203-213.
43. Turk V, Turk B, Turk D. 2001. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 20:4629-4633.
44. Vance JE, Peake KB. 2011. Function of the Niemann-Pick type C proteins and their bypass by cyclodextrin. Curr. Opin. Lipidol. 22:204-209.
45. Weidmann M, Mühlberger E, Hufert F. 2004. Rapid detection protocol for filoviruses. J. Clin. Virol. 30:94-99.
46. Wong AC, Sandesara RG, Mulherkar N, Whelan SP, Chandran K. 2010. A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. J. Virol. 84:163-175.